Which of the following is true regarding Fluoxetine?

Fluoxetine is indeed known for having the longest half-life among selective serotonin reuptake inhibitors (SSRIs). The extended half-life of fluoxetine is due to its active metabolite, norfluoxetine, which can remain in the body for an extended period, sometimes leading to less frequent dosing. This characteristic can be advantageous in clinical settings, as it can provide a more stable serum level of the medication and lower the risk of withdrawal symptoms if a dose is missed.

Moreover, this prolonged half-life is particularly important in the context of managing perinatal mental health, as it can help ensure a more consistent therapeutic effect during pregnancy and postpartum. Understanding the pharmacokinetics of fluoxetine and its implications for treatment in pregnant individuals or nursing mothers is essential for making informed clinical decisions.

The other options present different claims about fluoxetine that do not hold true when examined closely. For instance, fluoxetine does not have the shortest half-life compared to other SSRIs, and while it is frequently prescribed during pregnancy, it is not necessarily the most commonly prescribed SSRI in this population. Additionally, while it may not require significant dose adjustments for lactation due to its long half-life, considerations based on individual patient circumstances still apply.